Back to top
more

Omeros (OMER)

(Real Time Quote from BATS)

$3.30 USD

3.30
859,629

-0.87 (-20.86%)

Updated May 16, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OMER

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Omeros Corporation [OMER]

Reports for Purchase

Showing records 341 - 360 ( 423 total )

Company: Omeros Corporation

Industry: Medical - Products

Record: 341

06/27/2012

Daily Note

Pages: 3

Capital Raised

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 342

06/20/2012

Company Report

Pages: 8

Ophthalmology Expert''s Insights Support Attractive Risk:Reward For Second OMS302 Phase 3 Trial In Our View. Data Release in H2:12.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 343

06/06/2012

Daily Note

Pages: 6

IND Filed for OMS824 (PDE10 Inhibitor for Cognitive Disorders) with Phase 1 Data Anticipated by Year-end; Reiterate OUTPERFORM and $19 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 344

06/03/2012

Industry Report

Pages: 19

Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 345

05/21/2012

Industry Report

Pages: 17

MONTHLY PORTFOLIO UPDATE

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 346

05/20/2012

Industry Report

Pages: 4

MONTHLY PORTFOLIO UPDATE

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 347

05/11/2012

Daily Note

Pages: 8

Q1 Financials Uneventful, but Cash Runway Lasts Through Transforming Catalyst

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 348

05/10/2012

Daily Note

Pages: 3

1Q12 Financial Results

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 349

05/10/2012

Daily Note

Pages: 5

1Q12 Financial Results

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 350

05/04/2012

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 351

04/10/2012

Daily Note

Pages: 6

Initiation of Enrollment in Second OMS302 Phase 3 Trial Sets Timeline for Clinical Data Release in H2:12. Reiterate OUTPERFORM and $20 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 352

04/02/2012

Industry Report

Pages: 17

MONTHLY PORTFOLIO UPDATE - ELEMER PIROS

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 353

03/29/2012

Daily Note

Pages: 5

Issuance of Additional OMS302 Patent Further Strengthens Intellectual Property. Reiterate OUTPERFORM and $20 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 354

03/20/2012

Company Report

Pages: 8

Increasing Our Projections For OMS302 Due To Strong Clinical Profile And Increasing Procedure Volumes. Raising FV to $20 and Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 355

03/13/2012

Company Report

Pages: 10

`OMS302 Hits Primary and Secondary Endpoints in Phase 3 Trial.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 356

03/13/2012

Daily Note

Pages: 3

Pivotal Eye Data Achieved All Endpoints - Raising Target Price

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 357

03/13/2012

Company Report

Pages: 6

Pivotal Eye Data Achieved All Endpoints - Raising Target Price

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 358

02/23/2012

Daily Note

Pages: 6

27 Orphan GPCRs Have Been Unlocked.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 359

02/21/2012

Daily Note

Pages: 5

Receives Government Funding for Development of a Non-Addictive Analgesic.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 360

02/07/2012

Daily Note

Pages: 5

OMS302 Design Optimized To Increase Probability of Success. Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party